Integrated BioTherapeutics has received a five-year NIH research grant to develop human antibody therapeutics against staphylococcal enterotoxin B, a bacterial-derived toxin from Staphylococcus aureus
The project is a continuation of a biodefense-related project initiated by USAMRIID, an organization of the US Army Medical Research and Materiel Command, in September 2006 using AbD Serotec's custom monoclonal antibody services.
IBT will use a selection of Hucal-based antibodies originally generated by AbD Serotec against staphylococcal eneterotoxin B in in vitro and in vivo experiments to identify lead neutralising candidates and is expected to order additional antibody material as well as other services offered by AbD Serotec.
Staphylococcal enterotoxins are involved in a variety of human pathologies ranging from hospital and community-acquired infections, sepsis, toxic shock syndrome, to atopic dermatitis.
Staphylococcal enterotoxin B is also considered as a potential agent of bioterrorism.
Currently no vaccines or immunotherapeutics are available against staphylococcal toxins or S aureus infections.
The research collaboration between IBT and AbD Serotec follows a novel paradigm in the fight against these pathogens by targeting toxins released by bacteria which can distract the immune system and cause massive and even fatal damage.
"This grant allows us to continue a very promising project initiated by USAMRIID and AbD Serotec," said Javad Aman, president and CSO of IBT.
"IBT is extremely pleased to have access to AbD's unique technology for developing antibodies with therapeutic potential in this important medical area".
"Today's news marks yet another promising development of a pre-existing customer relationship of AbD Serotec," comments Achim Knappik, head of R+D at AbD Serotec.
"We look forward to work with Integrated BioTherapeutics on this promising project in the field of infectious diseases which is an interesting research market for AbD Serotec."
